6-[3-(4-Morpholinyl)Propyl]-2-(3-Nitrophenyl)-5-Thioxo-5,6,-Dihydro-7h-Thienol[2',3':4,5]Pyrrolo[1,2-C]Imidazol-7-One

Identification

Name
6-[3-(4-Morpholinyl)Propyl]-2-(3-Nitrophenyl)-5-Thioxo-5,6,-Dihydro-7h-Thienol[2',3':4,5]Pyrrolo[1,2-C]Imidazol-7-One
Accession Number
DB03507  (EXPT00294)
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Categories
Not Available
UNII
Not Available
CAS number
Not Available
Weight
Average: 456.538
Monoisotopic: 456.092596528
Chemical Formula
C21H20N4O4S2
InChI Key
UXGUZFZBZPPZGL-UHFFFAOYSA-N
InChI
InChI=1S/C21H20N4O4S2/c26-20-17-13-19-16(12-18(31-19)14-3-1-4-15(11-14)25(27)28)24(17)21(30)23(20)6-2-5-22-7-9-29-10-8-22/h1,3-4,11-13H,2,5-10H2
IUPAC Name
10-[3-(morpholin-4-yl)propyl]-4-(3-nitrophenyl)-11-sulfanylidene-5-thia-1,10-diazatricyclo[6.3.0.0²,⁶]undeca-2(6),3,7-trien-9-one
SMILES
[O-][N+](=O)C1=CC(=CC=C1)C1=CC2=C(S1)C=C1N2C(=S)N(CCCN2CCOCC2)C1=O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UTumor necrosis factor receptor superfamily member 1ANot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
4470566
PubChem Substance
46507367
ChemSpider
3668969
HET
703
PDB Entries
1ft4

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0214 mg/mLALOGPS
logP4.08ALOGPS
logP3.29ChemAxon
logS-4.3ALOGPS
pKa (Strongest Basic)6.54ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area83.53 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity123.13 m3·mol-1ChemAxon
Polarizability48.41 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9436
Blood Brain Barrier+0.7913
Caco-2 permeable-0.5957
P-glycoprotein substrateNon-substrate0.5061
P-glycoprotein inhibitor IInhibitor0.5981
P-glycoprotein inhibitor IIInhibitor0.5697
Renal organic cation transporterNon-inhibitor0.6489
CYP450 2C9 substrateNon-substrate0.8076
CYP450 2D6 substrateNon-substrate0.8008
CYP450 3A4 substrateSubstrate0.5851
CYP450 1A2 substrateNon-inhibitor0.7963
CYP450 2C9 inhibitorInhibitor0.6788
CYP450 2D6 inhibitorNon-inhibitor0.915
CYP450 2C19 inhibitorNon-inhibitor0.5206
CYP450 3A4 inhibitorNon-inhibitor0.5498
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8765
Ames testAMES toxic0.7279
CarcinogenicityNon-carcinogens0.7698
BiodegradationNot ready biodegradable0.9672
Rat acute toxicity2.5381 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5892
hERG inhibition (predictor II)Inhibitor0.5955
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as nitrobenzenes. These are compounds containing a nitrobenzene moiety, which consists of a benzene ring with a carbon bearing a nitro group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Nitrobenzenes
Direct Parent
Nitrobenzenes
Alternative Parents
Thienopyrroles / 2,3,5-trisubstituted thiophenes / Nitroaromatic compounds / Morpholines / Pyrroles / Heteroaromatic compounds / Trialkylamines / Thioureas / Amino acids and derivatives / Propargyl-type 1,3-dipolar organic compounds
show 7 more
Substituents
Nitrobenzene / Nitroaromatic compound / Thienopyrrole / 2,3,5-trisubstituted thiophene / Morpholine / Oxazinane / Pyrrole / Thiophene / Heteroaromatic compound / Organic nitro compound
show 25 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
C-nitro compound, morpholines, thienopyrroloimidazole (CHEBI:40211)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Tumor necrosis factor-activated receptor activity
Specific Function
Receptor for TNFSF2/TNF-alpha and homotrimeric TNFSF1/lymphotoxin-alpha. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC...
Gene Name
TNFRSF1A
Uniprot ID
P19438
Uniprot Name
Tumor necrosis factor receptor superfamily member 1A
Molecular Weight
50494.3 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on June 13, 2005 07:24 / Updated on December 01, 2017 15:14